EPILEPTIC MANIFESTATIONS INDUCED BY MIDAZOLAM IN THE NEONATAL PERIOD

Maria Augusta Montenegro, Marilisa M. Guerreiro, Jamil Pedro Siqueira Caldas, Maria Valeriana L. Moura-Ribeiro, Carlos Alberto M. Guerreiro

ABSTRACT - Antiepileptic drugs may cause worsening of epilepsy by aggravating pre-existing seizures or by triggering new seizure types. There are several reports of adverse effects related to midazolam, but only a few authors reported epileptic manifestations. We report four newborns seen at the Neonatal Intensive Care Unit of our University Hospital, who developed seizures a few seconds after the administration of midazolam. It is difficult to identify the patients at risk, but it is important to be aware and recognize this situation.

KEY WORDS: midazolam, seizures, neonatal period.

After this seizure she has never had any other epileptic manifestation. The follow up period is 4 months.

Patient 2. A preterm newborn with GA of 30 weeks and 4 days, Apgar score 2 and 8 in the first and fifth minutes of life, respectively, birth weight 1070g, was kept in the Neonatal Intensive Care Unit because he developed respiratory distress. During the first day of life he presented a seizure (characterized by clonic movements of the four limbs, which did not stop after being restrained, lasting about 1 to 2 minutes) a few seconds after midazolam (0.15 mg/kg) was administered intravenously for sedation. He had not had any other seizure before and neurologic examination showed hypotonia. Brain ultrasonography was normal. EEG was not performed due to technical problems. After this episode he has never had any other epileptic manifestation. The follow up period is 4 months.

Patient 3. A preterm newborn with GA of 27 weeks and 4 days, Apgar score 1, 5 and 8 in the first, fifth and tenth minutes of life, respectively, birth weight 620g, was kept in the Neonatal Intensive Care Unit because she developed hypoxic ischemia, meninges and respiratory disturbances. She had already had seizures since the first week of life (characterized by multifocal clonic movements), which were controlled with phenobarbital. Her last seizure was 3 weeks prior to the midazolam administration. In the third month of life (conceptional age of 44 weeks) she presented a seizure (characterized by clonic movements of the four limbs, which did not stop after being restrained, lasting about 1 to 2 minutes) a few seconds after midazolam (0.15 mg/kg) was administered intravenously for sedation. EEG was not performed due to technical problems. After this episode she has never had any other epileptic manifestation. The follow up period is 4 months.

Department of Neurology, Faculty of Medical Sciences (FMC), University of Campinas (UNICAMP), Campinas SP, Brazil.
tioned by clonic movements of the four limbs, which did not stop after being restrained, lasting about 2 minutes) a few seconds after midazolam (0.15 mg/kg) was administered intravenously for sedation. She needed a second dose of midazolam in the same day, and had another seizure (similar to the one described above) a few seconds after this second injection. Neurologic examination showed microcephaly, hypertonia and hyperactive reflexes. Brain ultrasonography was normal. EEG was not performed due to technical problems. Phenobarbital therapy was continued and after this episode she has never had any other epileptic manifestation. Follow up period is 6 months.

**Patient 4.** A preterm newborn with GA of 26 weeks, Apgar score 6 and 8 in the first and fifth minutes of life, birth weight 1040g, was kept in the Neonatal Intensive Care Unit because he developed severe hypoxic ischemic encephalopathy, respiratory disturbances, renal failure and pulmonary infection. He presented seizures (characterized by multifocal clonic movements and tonic posturing of the legs) in the first two days of life probably due to hypoxic ischemic encephalopathy and central nervous system (CNS) hemorrhagic lesions, which were controlled with phenobarbital (5 mg/kg/day). In the 4th day of life he presented a seizure (characterized by clonic movements of the four limbs, which did not stop after being restrained, lasting about 1 minute) a few seconds after midazolam (0.15 mg/kg) was administered intravenously for sedation. Neurological examination showed hypotonia and absent reflexes, but the patient was sedated with fentanyl when the examination was performed. Brain ultrasonography showed bilateral hemorrhagic lesions. EEG was not performed due to technical problems. Phenobarbital therapy was continued and after this episode he has never had any other epileptic manifestation. He died with 6 days of age.

**DISCUSSION**

Midazolam is a benzodiazepine with a short half-life that is used extensively for preoperative and procedure-related sedation. In the neonatal period it seems to have a longer half-life (6.25 hours) and an increase in its use for sedation, as well as an AED, has been observed in neonatal intensive care units.

There are several reports of adverse effects related to midazolam, but only a few authors reported epileptic manifestations 5-7.

We report four neonates who developed epileptic manifestations a few seconds after the administration of midazolam. Other possible causes of seizures such as hypoglycemia, hypocalcemia, infection, polycitemia, CNS malformations, hemorrhagic or ischemic lesions were investigated. Patient 4 was clinically unstable when the seizure induced by midazolam occurred, but the clear temporal relationship with the administration of midazolam suggests that this event was probably drug related.

Buts et al. described myoclonic movements of the four limbs observed in six neonates who received continuous intravenous infusion of midazolam, 2-48 hours after the midazolam infusion had been started. Engstrom reported a 27-year-old woman presenting a generalized tonic-clonic seizure (lasting 1-2 minutes) immediately following the intravenously administration of 2 mg of midazolam for sedation.

Despite the lack of video EEG monitoring during the events presented by our patients, we believe that they are truly epileptic in nature because the physician who witnessed the seizure tested them and the clonic movements could be felt after restraining the limb. Moreover, clonic seizures in the neonatal period consistently show a close relationship to EEG seizure discharges.

It should be emphasized that the epileptic manifestations occurred after a short period following the drug administration (usually an intravenous bolus injection) and this should be differentiated from a reversible encephalopathy characterized by poor visual tracking, depression of consciousness and involuntary movements (choreothetosis) associated with the withdrawal of prolonged intravenous midazolam and fentanyl administration 3.

There are no explanations why an AED may induce seizures. The relationship between the speed of the infusion and the occurrence of seizure might be a possibility, since it occurred after an intravenous bolus injection. Van den Anker and Sauer suggested that since midazolam decreases arterial pressure and heart rate in preterm infants, maybe it could be due to a decrease in cerebral blood flow. This hypothesis is speculative and a direct effect on the CNS cannot be excluded. We believe that in our patients the speed of the infusion of midazolam played an important role in the occurrence of this adverse event, because since we slowed down the infusion we have not observed new cases like these.

We conclude that it is difficult to identify the patients at risk, but it is important to be aware and recognize this situation.

**REFERENCES**